Roche to strengthen gene therapy portfolio with Spark Therapeutics acquisition
Swiss pharmaceutical giant Roche has reached a major agreement to acquire the U.S.-based gene therapy company Spark Therapeutics in an all-cash deal valued at $4.3 billion. Under the terms of the deal, Roche will purchase 100% of Spark Therapeutics for $114.50 per share. This acquisition is a strategic move to expand Roche’s capabilities in the […]